Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardio Diagnostics Holdings (CDIO) Research & Development (2022 - 2025)

Cardio Diagnostics Holdings' Research & Development history spans 4 years, with the latest figure at $2200.0 for Q1 2025.

  • For Q1 2025, Research & Development fell 79.7% year-over-year to $2200.0; the TTM value through Mar 2025 reached $20485.0, down 70.46%, while the annual FY2024 figure was $29125.0, 79.94% down from the prior year.
  • Research & Development for Q1 2025 was $2200.0 at Cardio Diagnostics Holdings, down from $5758.0 in the prior quarter.
  • Across five years, Research & Development topped out at $86665.0 in Q1 2023 and bottomed at $1130.0 in Q1 2022.
  • The 4-year median for Research & Development is $7280.0 (2024), against an average of $16688.8.
  • The largest annual shift saw Research & Development surged 7569.47% in 2023 before it plummeted 87.49% in 2024.
  • A 4-year view of Research & Development shows it stood at $31087.0 in 2022, then plummeted by 75.9% to $7492.0 in 2023, then dropped by 23.14% to $5758.0 in 2024, then tumbled by 61.79% to $2200.0 in 2025.
  • Per Business Quant, the three most recent readings for CDIO's Research & Development are $2200.0 (Q1 2025), $5758.0 (Q4 2024), and $5247.0 (Q3 2024).